New drug aims to shield vision during optic neuritis attacks
NCT ID NCT04762017
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a new drug called OCS-05 in 36 people with acute optic neuritis, a condition that inflames the optic nerve and can cause vision loss. Participants received OCS-05 or a placebo alongside standard steroid treatment for five days. The main goal was to check safety, and researchers also measured changes in retinal thickness to see if the drug might protect eye health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCS-05 (given intravenously with corticosteroids)
What this could lead to
If successful, this could point toward a treatment that protects vision during optic neuritis attacks.
What could go wrong
This is a small, early-phase safety study with only 36 people. It is not designed to prove the drug works, and results may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPTIC NEURITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU - Nice
Nice, 06000, France
-
CIC Neurosciences - La Pitié Salpêtrière
Paris, 75013, France
-
Foundation Rothschild
Paris, 75019, France
-
Hospices Civils de Lyon
Lyon, 69677, France